Immunoprecise Antibodies Ltd

ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. Its services include B cell sorting, screening and sequencing; custom, immune and naive phage display production and screening; bi-specific, tri-specific, VHH, and VNAR antibody manufacturing; antibody engineering; and antibody optimization and humanization. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

IPA reports record revenue and seeks funding for future growth

IPA's Q2 '23 earnings call highlighted record revenue, strategic program consolidation, and advancements in R&D. While facing cash needs and the need to raise funds, the company remains optimistic about future partnerships and the potential for data management transactions.

Immunoprecise Antibodies reports strong revenue growth and strategic collaborations

Immunoprecise Antibodies Ltd (IPA) had a strong quarter with revenue growth and valuable research collaborations, positioning the company for future success despite operational challenges.
IPA's focus on innovation, disruptive AI-driven collaborations, and strategic changes to boost profits highlight a positive growth trajectory and commitment to addressing unmet medical needs.

Immunoprecise Antibodies reports record revenue, eyes strategic partnerships for growth

IPA's Q4 '23 earnings call reflects strong revenue growth, strategic collaborations, and a focus on operational efficiency, positioning the company for future success.
While facing financial challenges and the need for fundraising, IPA's technological strengths, partnerships, and market opportunities offer avenues for growth and innovation.
The company's performance highlights resilience in the biotech sector, with a clear roadmap for enhancing shareholder value and advancing R&D capabilities.

Immunoprecise Antibodies Ltd posts strong Q1 earnings, eyes U.S. investors

Immunoprecise Antibodies Ltd (IPA) reports robust Q1 2024 earnings, marked by significant revenue growth and improved financial metrics. The company showcases strengths in strategic leadership, cost management, and expansion initiatives, while facing challenges in managing net losses and financial transparency. IPA has opportunities to capitalize on its strengths and attract more investors through the SEC shelf offering.

Immunoprecise Antibodies Ltd reports record Q2 revenue growth

IPA's Q2 2024 earnings call showcased robust revenue growth, operational improvements, and strategic initiatives driving the company forward.
While facing industry challenges, IPA's focus on client trust, cost management, and innovation positions it well for future success.
The company's commitment to governance, shareholder engagement, and exploring new revenue streams highlights a proactive approach to growth.

Immunoprecise Antibodies Ltd (IPA) reports strong Q3 performance and strategic investments

Immunoprecise Antibodies Ltd (IPA) delivered a robust performance in Q3 2024, marked by revenue growth, profit margin improvements, and strategic investments in BioStrand. While facing a net loss, IPA maintains a healthy cash balance and focuses on R&D efficiency. The company's strengths in innovation and customer commitment position it well for future growth, with opportunities to leverage its momentum for market expansion.

Immunoprecise Antibodies (IPA) reports 19% revenue growth in 2024

Immunoprecise Antibodies Ltd (IPA) delivered strong financial performance in fiscal year 2024, with revenue growth, reduced operating expenses, and successful product launches. Strategic collaborations and industry recognition highlight IPA's competitive strengths. Addressing commercialization challenges and seizing growth opportunities will be key focus areas for future success.

Immunoprecise Antibodies reports revenue growth and strategic advancements in Q1

IPA's Q1 2025 performance reflects revenue growth driven by VHH antibody programs and strategic inventory management.
The company's strengths lie in its AI-driven platform, strong pipeline, and balanced revenue generation models.
Challenges include maintaining financial consistency, effective inventory management, and staying competitive in the evolving market.
Opportunities for IPA include sustained growth through fee-for-service work, revenue diversification via licensing, and leadership in biotechnology innovation.

Immunoprecise Antibodies reports revenue growth amidst financial challenges in Q2 2025

Immunoprecise Antibodies Ltd's Q2 2025 performance reflects revenue growth but also increased expenses and a net loss, highlighting financial challenges.
Strategic strengths include industry profile enhancement, strong research collaborations, and a commitment to innovation.
Challenges lie in cost management, operational realignment post-divestiture, and the need for revenue growth.
Opportunities exist in collaborations with semiconductor companies, market expansion through BioStrand, and strategic financial restructuring.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service, therapeutic antibody discovery and development, today announced that it will be presenting at the H.C. Wainwright Annual Global Investment Conference being held virtually on September 13-15, 2021. Jennifer Bath, CEO of ImmunoPrecise, will provide an overview of the Company's business during the live presentation and will be available to

ImmunoPrecise Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13-15, 2021 (Virtual Conference)

ImmunoPrecise Announces Participation at the H.C. Wainwright 23nd Annual Global Investment Conference on September 13-15, 2021 (Virtual Conference)

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announces the promotion of Dr. Barry Duplantis, Ph.D., to VP of Client Relations and welcomes Ms. Carla Dahl as VP of Marketing. Dr. Duplantis, who joined the Company in 2018, was previously ImmunoPrecise's Director of Client Relations, where he was responsible for client interactions

ImmunoPrecise Welcomes Vice President of Client Relations and Vice President of Marketing to its Leadership Team, Accelerating Its Growth and Expansion Plans

ImmunoPrecise Antibodies Ltd. (IPA) CEO Jennifer Bath on Q4 2021 Results - Earnings Call Transcript

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced financial results for the full fiscal year 2021 ended April 30, 2021. Fiscal 2021 Financial Summary* Earned revenues of $17.9 million, a 27% increase which includes a sale through Talem of an internally generated therapeutic antibody for $1.2 million, core CRO business up 19%

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2021

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) skyrocketed 136% on Thursday after the company announced its TATX-03 PolyTope Therapy demonstrated potent pseudovirus neutralizing activity against the COVID-19 Delta variant in vitro.

ImmunoPrecise SkyRockets On Delta Variant Therapy News: What's Next?

Today's impressive move in ImmunoPrecise's stock price has led investors in IPA stock to consider what is driving these price changes. The post IPA Stock: 7 Things to Know About Covid Vaccine Stock ImmunoPrecise as Shares Rocket 120% appeared first on InvestorPlace.

IPA Stock: 7 Things to Know About Covid Vaccine Stock ImmunoPrecise as Shares Rocket 120%

ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) is surging higher Thursday after the company highlighted the ability of its antibody cocktail to potentially neutralize COVID-19 variants.  ImmunoPrecise Antibodies' antibody cocktail, TATX-03 PolyTope, was developed for the potential prevention and treatment of SARS-CoV-2.

Why ImmunoPrecise Antibodies Stock Is Soaring Today

Immunoprecise Antibodies Ltd (NASDAQ: IPA) has announced new results from its TATX-03 PolyTope Therapy, demonstrating potent pseudovirus neutralizing activity against the SARS-CoV-2 Delta (B.1.617.2) variant. The therapy is a four monoclonal antibody cocktail developed for the potential prevention and treatment of COVID-19.

Immunoprecise Stock Soars As COVID-19 Antibody Cocktail Shows Neutralizing Activity Against Delta Variant In Animal Study

The stock price of ImmunoPrecise Antibodies LTD.  (NASDAQ: IPA) increased by over 30% pre-market.

IPA Stock Increases Over 30% Pre-Market: Why It Happened

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) today announced new results from its TATX-03 PolyTope™ Therapy, a four monoclonal antibody cocktail developed for the potential prevention and treatment of SARS-CoV-2, demonstrating potent pseudovirus neutralizing activity against the SARS-CoV-2 Delta (B.1.617.2) variant. The Company anticipated viral evolution leading to novel SARS-CoV-2 variants of concern throu

ImmunoPrecise's PolyTope™ TATX-03 Antibody Cocktail Potently Neutralizes SARS-CoV-2 Delta Variant in in vitro Pseudovirus Assays

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA) (TSX VENTURE:IPA) a leader in full-service, therapeutic antibody discovery and development, today announced the Company will host a conference call to discuss its financial results and business highlights for the full fiscal year 2021, on Wednesday, July 28, 2021, after the close of market. The financial results will be issued in a press release prior to the call. ImmunoPrecise manag

ImmunoPrecise to Report Financial Results and Business Highlights for Fiscal Year 2021

Enerplus

VICTORIA, British Columbia--(BUSINESS WIRE)---- $ERF.PA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) the market leader in full-service therapeutic discovery and development and Eurofins Discovery, the leading provider of products and services to the drug discovery industry and a Eurofins Scientific (Paris:ERF) company, announced a commercial collaboration. Leveraging complementary strengths in Eurofins Discovery's in vitro pharmacology services and ImmunoPrecise's

Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) today announced additional results from its in vivo hamster challenge efficacy study of TATX-03a PolyTope™ Therapy, a four monoclonal antibody cocktail being developed for the potential prevention and treatment of SARS-CoV-2, demonstrating reduced bronchitis and tracheitis inflammation severity. The Company concurrently announced optimization results of TATX-03 coc

Histopathology Preclinical Data from ImmunoPrecise's Polytope™ Program Confirms Lung Inflammation Reduction

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) today announced the results from in vitro characterizations investigating TATX-21, a novel potential first-in-class antibody for Atherosclerosis Cardiovascular Disease (ACVD), will be presented in partnering meetings at the 2021 BIO International Convention, June 14-18, 2021. Data will be presented on investigational antibodies known as TATX-21, a diverse pool of a

Preclinical Data from ImmunoPrecise's Drug Pipeline to be Presented During the BIO International Partnering Event

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, announced today that Dr. Yasmina Abdiche, Chief Scientific Officer, will resign effective July 1, 2021, to pursue other opportunities, and that the board of directors has appointed Dr. Ilse Roodink to take over the role of Chief Scientific Officer. Since 2019, Dr. Ilse Roodink has served as

ImmunoPrecise Announces Appointment of Dr. Ilse Roodink to the Role of Chief Scientific Officer and Resignation of Dr. Yasmina Abdiche

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that Dr. Dion Neame has joined the company's Strategic Advisory Board (SAB). Dr. Neame joins at a significant time, as the company continues to focus its energy on building essential partnerships and expanding its rapidly growing share of the market. He will play a key role i

ImmunoPrecise Names Dr. Dion Neame to Strategic Advisory Board

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA) (TSX venture: IPA) announces the completion of an efficacy-driven, preclinical study demonstrating further evidence of the in vivo efficacy of a four monoclonal antibody cocktail against non-overlapping epitopes, utilizing an optimized formulation and, for the first time, demonstrating therapeutic synergy of the cocktail components in vivo. Highlights of the study include: Completed

ImmunoPrecise Moves SARS-CoV-2 PolyTope™ Cocktail Program's Path Toward IND Filing

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that it has selected and retained LifeSci Advisors as investor relations agent of record. Jennifer Bath, President and CEO of ImmunoPrecise Antibodies commented, “We are pleased to partner with LifeSci Advisors for our investor relations advisory needs during this important s

ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record

ImmunoPrecise Antibodies Ltd's (NASDAQ: IPA) subsidiary Talem Therapeutics LLC has advanced developing a candidate referred to as TATX-112, against an undisclosed target, into formal lead candidate characterization. The target is a protein receptor that is overexpressed in a variety of types of deadly cancers.

ImmunoPrecise Launches TATX-112 Antibody Program For Cancer, Alzheimer's Disease

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that its subsidiary Talem Therapeutics LLC (“Talem”) has advanced development of a candidate panel of vetted, novel, therapeutic antibodies, collectively referred to as TATX-112, against an undisclosed target, into formal lead candidate characterization. It is well documented

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer's Disease

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced the identification of antibody 23-H7, which preclinical data obtained to date indicates provides strong, protective anti-viral effects in SARS-CoV-2 (COVID-19) infected Syrian hamsters via an uncommon mechanism of action. While 23-H7 is able to perturb the interaction between

ImmunoPrecise Identifies a Unique Antibody, 23-H7, That Demonstrates In Vivo Efficacy, an Alternative Mechanism of Action and Binds all Tested SARS-CoV-2 Variants of Concern

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced financial results for the third quarter of its 2021 fiscal year ended January 31, 2020. Q3 Fiscal 2021 Financial Highlights: Increased revenue for the nine months ended January 31st, 2021 by 32% to $13,035,522. Record adjusted EBITDA for the nine months ended January 31st, 20

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter of 2021 Fiscal Year

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today has confirmed the results of an additional PolyTope™ antibody interaction analysis against SARS-CoV-2 spike protein variants of concern. Twenty-seven extensively characterized, proprietary, lead candidate antibodies have been generated and analyzed by ImmunoPrecise in its preclinical s

ImmunoPrecise Antibodies Announces Results from a Comprehensive Screening of 27 Proprietary Anti-SARS-CoV-2 Therapeutic Antibodies

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery and development, today announced that it will be presenting at the H.C. Wainwright Global Life Sciences Conference being held virtually on March 9-10, 2021. Jennifer Bath, CEO of ImmunoPrecise, will provide an overview of the Company's business during the live presentation and will be available to participate in o

News for Immunoprecise Antibodies Ltd Stock (IPA)